Thanks for signing up!
FT Digital Edition: our digitised print edition
。快连下载安装对此有专业解读
下一代疗法比拼升级Infigratinib并非唯一挑战Vosoritide的选手，在ACH治疗赛道，多款下一代疗法正加速推进，从周剂注射到高选择性靶向，行业的研发比拼正不断升级，Vosoritide的垄断时代已进入倒计时。
For security reasons this page cannot be displayed.
Copyright © 1997-2026 by www.people.com.cn all rights reserved